Seite 1 von 17 Ergebnisse
Introduction
Malignancies during childhood constitute the 2nd cause of death, following injuries worldwide. According to epidemiological data, 300,000 new cases of neoplasia present themselves every year in children and teenagers under 19 years of age1, 160,000 of which concern children under the
This is a randomized open-label Phase 2 trial with parallel design using no-treatment group as control. Subjects in the treatment arm will receive subcutaneous G-CSF with the dosage of 10 microgram/kg/day, for 5 continuous days in the first week. The second dosage will be given in the 12 week. If
Gemcitabine-based combination therapy have been used to prolong survival for patient with pancreatic cancer. In early 2010s, gemcitabine plus nab-paclitaxel (GnP) combination regimen have been introduced based on the results of randomized phase III clinical trial that showed survival benefit than
Background:
In late March and early April 2009 an outbreak of a novel influenza virus designated A/H1N1 influenza (popularly known as swine flu) was reported in Mexico, with subsequent cases observed in many countries, leading to the declaration by the World Health Organization of a worldwide
- Brief Protocol: Treat the patients taking Taxotere+Epirubicin +Cyclophosphamide (TEC) treatment or Taxotere+Epirubicin (TE)treatment chemotherapy with the study medicine or positive control during the period between two chemotherapy treatments.
- Targeted patients: breast cancer
- Subjects were
Neoadjuvant therapy has become the consensus treatment for individuals with locally advanced unresectable disease and borderline resectable disease. Typical regimens utilize those that are used in the metastatic setting for pancreatic cancer, such as FOLFIRINOX (5-FU, Leucovorin, Irinotecan, and
In Mexico, cervical cancer (CC) is the second most frequent cause of death among women, with a mortality rate of 4000 women/year. Among the patients attended by the INCan, 80% are diagnosed with locally advanced CC and 30% of these present comorbidities. Hypertension may be present in 20% of
In Mexico, cervical cancer (CC) is the second most frequent cause of death among women, with a mortality rate of 4000 women/year. Concerning the treatment of these patients, there is evidence about the benefit of addition of chemotherapy to radiotherapy in patients with locally advanced CC, with an
OUTLINE: This is a multi-center study.
EXPERIMENTAL ARM A:
- Oxaliplatin 85 mg/m^2 over 2-4 hours
- Irinotecan 165 mg/m^2 over 90 minutes
- 5-FU 2,400 mg/m^2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
- Arm A will receive ramucirumab (RAM)
INTRODUCTION 1.1 Background Myelodysplastic syndrome (MDS) is characterized by deficiencies in blood cell production that can lead to anemia, which may necessitate regular transfusions of red blood cells (RBCs) as supportive therapy. While this treatment can be life-saving, since the body has no
Preclinical studies have demonstrated that nab-paclitaxel may play a role in sensitizing the tumor to chemotherapeutic agents and specifically increases the antitumor efficacy when combined with gemcitabine. While the mechanism of action for the synergy is unclear, preclinical studies have generated
So far, granulocyte colony stimulating factor (G-CSF) is still currently the only effective and security therapy drug for neutropenia caused by cancer chemotherapy. At present, the widely used G-CSF products are of such short-acting G-CSF product in China. However, there existed some shortcoming
Improved therapeutic options for advanced pancreatic adenocarcinoma treatment need to continue to be investigated. Since 1997, gemcitabine has been the agent of choice for first-line therapy in advanced pancreatic cancer, with a median survival of 5.7 months, and a 20% 1-year survival (Eli Lilly
1. Patients
1.1. Patients
CML patients will be included according to the following inclusion criteria: a) patients of both sexes, b) age between 18 and 80 years, c) treated with imatinib or nilotinib, d) included in the follow-up in the Divisions / Units of Hematology involved in the project e) able
OBJECTIVES:
Primary
- To develop a population pharmacokinetic model for paclitaxel administered as paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) to a large population of patients with advanced or refractory cancer to characterize the inter-individual pharmacokinetic